186P Oncologists’ agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2- early breast cancer

Abstract

for BCSS (P¼0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR; 95% 2.21 CI 1.12-4.37, P¼0.023).Conclusions: This study analysed a large cohort of patients and the results suggest a significant difference in BCSS only in the ER-positive subgroup according to HER2 status. Although patients with T1b tumours have an excellent prognosis, HER2 and ER status may indicate that patients with small, node-negative breast cancer should be considered for treatment with trastuzumab.Legal entity responsible for the study: The authors.